免费不卡中文字幕在线|久久做人人做人人综合|初尝黑人嗷嗷叫中文字幕|国产成人v片视频在线观看|欧美日本国产VA高清视频|亚洲国产精品国自产拍AV|国产欧美精品一区二区色综合|微拍国产私拍福利88精品视频

  • <button id="0gwi0"></button>
    <tfoot id="0gwi0"></tfoot>
  • <dl id="0gwi0"><acronym id="0gwi0"></acronym></dl>
    <li id="0gwi0"></li>
    <rt id="0gwi0"><acronym id="0gwi0"></acronym></rt>
  • <rt id="0gwi0"></rt>
  • Beagle proves brave test subject for new Australian cancer drug

    Source: Xinhua| 2018-09-24 14:09:56|Editor: Chengcheng
    Video PlayerClose

    SYDNEY, Sept. 24 (Xinhua) -- Hoover, a 10-year-old beagle from Australia, is the first patient in the world to receive a new nanomedicine drug which could revolutionize the treatment of prostate cancer.

    Hoover was chosen for the trial by the University of Queensland (UQ) which was released on Monday, because dogs -- like humans -- naturally develop prostate cancer in old age.

    The nanomedicine Hoover received attaches itself to certain proteins found in prostate cancer, meaning treatments such as chemotherapy can be more effectively targeted.

    "Chemotherapy is a common treatment for most cancers," associate professor Kris Thurecht from UQ said.

    "Unfortunately, it can also cause serious side effects because it is not always able to differentiate cancer cells from the healthy ones, sometimes damaging healthy cells in the process."

    The cutting edge field of nanomedicine offers the potential to target only the cancer cells with minimal impact on healthy cells.

    Thurecht said that so far pre-clinical tests have been highly successful in treating prostate cancer in the laboratory, leading in some cases to total remission.

    Director of Brisbane Veterinary Specialist Centre and the Australian Animal Cancer Foundation Rod Straw said that Hoover could prove to be the vanguard for a revolution in health care.

    "Cases like Hoover's are very important to cancer research," Straw said.

    "We can learn to develop cancer treatments for not only pets but humans as well and our best friends may hold the key."

    TOP STORIES
    EDITOR’S CHOICE
    MOST VIEWED
    EXPLORE XINHUANET
    010020070750000000000000011100001374896941